Guiyang Xintian Pharmaceutical Co.,Ltd.

SZSE:002873 Stock Report

Market Cap: CN¥2.3b

Guiyang Xintian PharmaceuticalLtd Past Earnings Performance

Past criteria checks 1/6

Guiyang Xintian PharmaceuticalLtd has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.7% per year. Guiyang Xintian PharmaceuticalLtd's return on equity is 5.2%, and it has net margins of 6.5%.

Key information

2.5%

Earnings growth rate

2.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.7%
Return on equity5.2%
Net Margin6.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Apr 19
Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Recent updates

Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%

Oct 01
Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%

Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Jun 05
Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Apr 19
Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump

Mar 11
Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump

Revenue & Expenses Breakdown

How Guiyang Xintian PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002873 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248395451045
30 Jun 248706551447
31 Mar 249237157039
31 Dec 239548158938
30 Sep 239949459532
30 Jun 231,08910067526
31 Mar 231,04710664822
01 Jan 231,08811267522
30 Sep 221,09411768121
30 Jun 221,04011165320
31 Mar 221,00410662923
01 Jan 2297010160820
30 Sep 2195410259619
30 Jun 219029656117
31 Mar 218659653713
31 Dec 207517447413
30 Sep 20726634847
30 Jun 207116245714
31 Mar 207125745918
31 Dec 197737149221
30 Sep 197617647925
30 Jun 197397347226
31 Mar 197007144531
31 Dec 186947143732
30 Sep 186786941434
30 Jun 186776941140
31 Mar 186916843828
31 Dec 176826644123
30 Sep 176806744716
30 Jun 17665624590
31 Mar 17641604350
31 Dec 16633574320
30 Sep 16615594150
30 Jun 16565413970
31 Mar 16536413780
31 Dec 15522423670
30 Sep 15509443560
30 Jun 15496473450
31 Mar 15475403310
31 Dec 14454333170
31 Dec 13406152880

Quality Earnings: 002873 has a large one-off gain of CN¥26.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 002873's current net profit margins (6.5%) are lower than last year (9.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002873's earnings have grown by 2.5% per year over the past 5 years.

Accelerating Growth: 002873's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002873 had negative earnings growth (-42.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


Return on Equity

High ROE: 002873's Return on Equity (5.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies